NeoGenomics announced that it is participating as a designated laboratory in the NCI-Molecular Analysis for therapy choice precision medicine cancer treatment clinical trial. In NCI-MATCH, patients are assigned to receive treatment based on gene changes found in their tumors. The trial is being co-led by the National Cancer Institute, or NCI, part of the National Institutes of Health, and the ECOG-ACRIN Cancer Research Group. The goal of NCI-MATCH is to determine the effectiveness of treating patients based on specific tumor gene changes, independent of cancer type. Designated gene sequencing laboratories such as NeoGenomics identify potentially eligible patients being treated at clinical sites participating in the NCI-MATCH trial, through genomic testing. Such testing is performed at the request of the physician as part of a patient’s ongoing cancer care. Tumor gene testing by a designated lab is the only pathway for patients to enroll into the trial.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.